Next Gen KRAS G12C-mutated inhibitors are already surpassing the first generation cohort.

返回会议原文

返回会议

M. Elisabeth· @ChildrenNeedUs_ · X·2026-10-27 00:12· 2 天前评分70

divarasib

正文 · 原文

Next Gen KRAS G12C-mutated inhibitors are already surpassing the first generation cohort.

Divarasib came out of
Genentech/Roche labs.

#ESMO26 #ESMO2026

13 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

引用@

Original Article: Divarasib as Compared with Sotorasib or Adagrasib in 𝘒𝘙𝘈𝘚 G12C–Mutated NSCLC (phase 3 Krascendo 1 trial) https://nej.md/4BiCvbk #ESMO26 | @myESMO

在 X 查看被引用的帖子

来源：M. Elisabeth · x.com